US LNG exports surge but will buyers in China turn up?
Camille L. Bedrosian, the Chief Medical (TASE:BLWV) Officer of Amylyx Pharmaceuticals , Inc. (NASDAQ:AMLX), has recently sold shares of the company. According to a filing with the Securities and Exchange Commission, Bedrosian sold 12,425 shares of common stock on March 31, 2025. The shares were sold at a weighted average price of $3.4674, with the transaction totaling $43,082. The stock, currently trading at $3.78, has shown resilience with a 27% gain over the past year despite recent volatility. InvestingPro analysis indicates the stock is currently undervalued, with a "Fair" overall financial health score.
The sale was conducted to cover tax withholding obligations related to the vesting of restricted stock units, as noted in the filing. This transaction was automatic and not at the discretion of Bedrosian. Following the sale, Bedrosian holds 194,375 shares of Amylyx Pharmaceuticals directly. The company, with a market capitalization of approximately $296 million, maintains a strong liquidity position with a current ratio of 6.67. For deeper insights into insider transactions and comprehensive financial analysis, check out the detailed Pro Research Report available on InvestingPro.
In other recent news, Amylyx Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration has lifted the clinical hold on its Phase 1 trial for AMX0114, a potential treatment for amyotrophic lateral sclerosis (ALS). This decision allows the company to proceed with patient screening, enrollment, and dosing at trial sites across the United States. The trial, named LUMINA, will also commence in Canada and is designed as a multicenter, randomized, placebo-controlled study. It aims to assess the safety and biological activity of AMX0114, with approximately 48 individuals with ALS participating. The study will use a 3:1 randomization to administer either the investigational drug or a placebo. The trial will also monitor changes in neurofilament light levels, a biomarker for ALS. Amylyx expects to share early cohort data from the LUMINA trial within the year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.